Business
Schrödinger to Present Preclinical Data at AACR Annual Meeting
Presentations include preclinical data on Wee1/Myt1 inhibitor SGR-3515 and SOS1 inhibitor SGR-4174 NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq:
About this update from Schrodinger, Inc.
[{"type":"text","content":"\nPresentations include preclinical data on Wee1/Myt1 inhibitor SGR-3515 and SOS1 inhibitor SGR-4174\n\n NEW YORK--(BUSINESS WIRE)--\nSchrödinger, Inc. (Nasdaq: SDGR) today announced that new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, and SGR-4174, its SOS1 inhibitor, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25 - 30, 2025 in Chicago, IL.\n\nThe SGR-3515 presentation will include data demonstrating that an optimized, intermittent dosing schedule of SGR-3515 resulted in an improved therapeutic index in preclinical oncology models. Preclinical data also showed that SGR-3515 has a differentiated profile supporting continued development as a potential therapy for patients with advanced solid tumors. A Phase 1 clinical trial in this patient population is ongoing, and Schrödinger expects to report initial clinical data from the trial in the second half of 2025.\n\nData will also be presented on the development of a machine learning model that predicts the response to drug combinations between Wee1 and other drugs in a large group of cell line models in selected cancer types. Additionally, the model identified several compounds as synergistic with Wee1 in new cancer settings which may be of future interest.\n\nThe SGR-4174 presentation will include data characterizing SGR-4174 in preclinical oncology models. The SOS1 protein plays a critical role in the activation and regulation of the KRAS gene. Inhibition of SOS1 is considered a potential therapeutic combination strategy for the treatment of KRAS-driven cancers. Preclinical data suggest SGR-4174 has a differentiated profile and support its continued development as a potential therapy for patients with KRAS mutant cancers and in rare diseases arising from KRAS pathway mutations. This is the first preclinical data presentation for SGR-4174.\n\nDetails of the data presentations are as follows:\n\nPresentation Title: Optimization of therapeutic index of SGR-3515, a first-in-class Wee1/Myt1 inhibitor through intermittent dosing for monotherapy and combination with chemotherapy in xenograft tumor models\nAbstract Number: #3025\nPresentation Date and Time: Monday, April 28, 2025, 2-5PM CST (3-6PM ET)\nLocation: Poster Section 20\nSession Title: Kinase and Phosphatase Inhibitors 2\n\nPresentati...